Manufacturer of Controlled Substances; Notice of Application, 388-389 [05-72]
Download as PDF
388
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
investigation is sold at the retail level)
representative consumer organizations
have the right to appear as parties in
Commission antidumping
investigations. The Secretary will
prepare a public service list containing
the names and addresses of all persons,
or their representatives, who are parties
to this investigation upon the expiration
of the period for filing entries of
appearance.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
section 207.7(a) of the Commission’s
rules, the Secretary will make BPI
gathered in this investigation available
to authorized applicants representing
interested parties (as defined in 19
U.S.C. 1677(9)) who are parties to the
investigation under the APO issued in
the investigation, provided that the
application is made not later than seven
days after the publication of this notice
in the Federal Register. A separate
service list will be maintained by the
Secretary for those parties authorized to
receive BPI under the APO.
Conference.—The Commission’s
Director of Operations has scheduled a
conference in connection with this
investigation for 9:30 a.m. on January
19, 2005, at the U.S. International Trade
Commission Building, 500 E Street,
SW., Washington, DC. Parties wishing to
participate in the conference should
contact Betsy Haines (202) 205–3200 not
later than January 14, 2005, to arrange
for their appearance. Parties in support
of the imposition of antidumping duties
in this investigation and parties in
opposition to the imposition of such
duties will each be collectively
allocated one hour within which to
make an oral presentation at the
conference. A nonparty who has
testimony that may aid the
Commission’s deliberations may request
permission to present a short statement
at the conference.
Written submissions.—As provided in
sections 201.8 and 207.15 of the
Commission’s rules, any person may
submit to the Commission on or before
January 24, 2005, a written brief
containing information and arguments
pertinent to the subject matter of the
investigation. Parties may file written
testimony in connection with their
presentation at the conference no later
than three days before the conference. If
briefs or written testimony contain BPI,
they must conform with the
requirements of sections 201.6, 207.3,
and 207.7 of the Commission’s rules.
The Commission’s rules do not
authorize filing of submissions with the
Secretary by facsimile or electronic
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
means, except to the extent permitted by
section 201.8 of the Commission’s rules,
as amended, 67 FR 68036 (November 8,
2002).
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the investigation must
be served on all other parties to the
investigation (as identified by either the
public or BPI service list), and a
certificate of service must be timely
filed. The Secretary will not accept a
document for filing without a certificate
of service.
Authority: This investigation is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.12 of the
Commission’s rules.
By order of the Commission.
Issued: December 18, 2004.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 05–37 Filed 1–3–05; 8:45 am]
BILLING CODE 7020–02–P
Science Labs, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–58 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated July 28, 2004 and
published in the Federal Register on
August 10, 2004, (69 FR 48521),
Applied Science Labs, Inc., A Division
of Alltech Associates Inc., 2701
Carolean Industrial Drive, State College,
Pennsylvania 16801, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substance:
Drug
Schedule
Heroin (9200) ................................
Cocaine (9041) .............................
Codeine (9050) .............................
Meperidine (9230) .........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
II
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Applied Science Labs, Inc. to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Applied
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on October 28,
2004, Cambrex Charles City, Inc., 1205
11th Street, Charles City, Iowa 50616,
made application by renewal and on
October 13, 2004 by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
the basic classes of controlled
substances listed:
Drug
Amphetamine (1100) ......................
Methylphenidate (1724) .................
Dextropropoxyphene (9273) ..........
Fentanyl (9801) ..............................
Schedule
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, United
States Department of Justice,
Washington, DC 20537, Attention:
Federal Register Representative, Office
of Liaison and Policy (ODLR) and must
be filed no later than March 7, 2005.
E:\FR\FM\04JAN1.SGM
04JAN1
389
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–72 Filed 1–3–05; 8:45 am]
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on October
28, 2004, Cambrex Charles City, Inc.,
1205 11th Street, Charles City, Iowa
50616, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in Schedule
II.
The company plans to import the
phenylacetone to manufacture
amphetamine for distribution to its
customers.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections or
requests for hearing may be addressed,
in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, United States
Department of Justice, Washington, DC
20537, Attention: DEA Federal Register
Representative, Office of Liaison and
Policy (ODLR) and must be filed no later
than February 3, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–68 Filed 1–3–05; 8:45 am]
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–73 Filed 1–3–05; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 21, 2004, and
published in the Federal Register on
August 10, 2004, (69 FR 48521–48522),
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as a bulk
manufacturer of the basic classes of
controlled substances listed below:
Schedule
Drug
Marihuana (7360) ...........................
Tetrahydrocannabinols (7370) .......
I
I
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cayman Chemical Company to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cayman Chemical
Company to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 28, 2004, and
published in the Federal Register on
July 13, 2004, (69 FR 42067–42068),
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed below:
Drug
Tetrahydrocannabinols (7370) .......
Dihydromorphine (9145) ................
Hydromorphone (9150) ..................
Fentanyl (9801) ..............................
Schedule
I
I
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–66 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\04JAN1.SGM
04JAN1
Agencies
[Federal Register Volume 70, Number 2 (Tuesday, January 4, 2005)]
[Notices]
[Pages 388-389]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-72]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 28, 2004, Cambrex
Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made
application by renewal and on October 13, 2004 by letter to the Drug
Enforcement Administration (DEA) for registration as a bulk
manufacturer of the basic classes of controlled substances listed:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100).......................... II
Methylphenidate (1724)...................... II
Dextropropoxyphene (9273)................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: Federal Register Representative,
Office of Liaison and Policy (ODLR) and must be filed no later than
March 7, 2005.
[[Page 389]]
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-72 Filed 1-3-05; 8:45 am]
BILLING CODE 4410-09-P